Catalent adds fast-dissolve tech to oral dose arsenal

Adding to its store of technology weapons, Catalent Pharma can now offer fast-dissolve tablet technology to clients. It obtained the development rights to Lyopan from Pantec.

The lyophilized tablets are used for such OTC products as allergy treatments and travel medications, says Catalent. The technology uses less water than other oral dose technologies, reducing not just energy consumption but also sublimation and drying time.  

Lyopan adds to the oral dose technology subset of Catalent's drug delivery technology offerings. Among them are Zydis fast dissolve, a freeze-dried oral solid dosage form that disperses in the mouth, without water.

The manufacturing and packaging contractor announced last fall a deal with digital-ID solutions provider Digimarc for so-called media-enhanced packaging. The technology incorporates coding that allows consumers can connect via smart phone to product content that supplements label information.

- here's the Catalent release

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.